A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients
dc.contributor.buuauthor | Pehlivan, Yavuz | |
dc.contributor.buuauthor | Öksüz, Mustafa Ferhat | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAG-8227-2021 | tr_TR |
dc.contributor.scopusid | 57220381538 | tr_TR |
dc.contributor.scopusid | 56016440100 | tr_TR |
dc.date.accessioned | 2023-06-08T07:32:03Z | |
dc.date.available | 2023-06-08T07:32:03Z | |
dc.date.issued | 2016-05-16 | |
dc.description | Çalışmada 24 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. | tr_TR |
dc.description.abstract | In this multicenter, retrospective study, we evaluated the efficacy and safety of biologic therapies, including anti-TNFs, in secondary (AA) amyloidosis patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). In addition, the frequency of secondary amyloidosis in RA and AS patients in a single center was estimated. Fifty-one AS (39M, 12F, mean age: 46.7) and 30 RA patients (11M, 19F, mean age: 51.7) with AA amyloidosis from 16 different centers in Turkey were included. Clinical and demographical features of patients were obtained from medical charts. A composite response index (CRI) to biologic therapy-based on creatinine level, proteinuria and disease activity-was used to evaluate the efficacy of treatment. The mean annual incidence of AA amyloidosis in RA and AS patients was 0.23 and 0.42/1000 patients/year, respectively. The point prevalence in RA and AS groups was 4.59 and 7.58/1000, respectively. In RA group with AA amyloidosis, effective response was obtained in 52.2 % of patients according to CRI. RA patients with RF positivity and more initial disease activity tended to have higher response rates to therapy (p values, 0.069 and 0.056). After biologic therapy (median 17 months), two RA patients died and two developed tuberculosis. In AS group, 45.7 % of patients fulfilled the criteria of good response according to CRI. AS patients with higher CRP levels at the time of AA diagnosis and at the beginning of anti-TNF therapy had higher response rates (p values, 0.011 and 0.017). During follow-up after anti-TNF therapy (median 38 months), one patient died and tuberculosis developed in two patients. Biologic therapy seems to be effective in at least half of RA and AS patients with AA amyloidosis. Tuberculosis was the most important safety concern. | en_US |
dc.identifier.citation | Pamuk, Ö. N. vd. (2016). "A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients". Rheumatology International, 36(7), 945-953. | en_US |
dc.identifier.endpage | 953 | tr_TR |
dc.identifier.issn | 0172-8172 | |
dc.identifier.issn | 1437-160X | |
dc.identifier.issue | 7 | tr_TR |
dc.identifier.pubmed | 27221456 | tr_TR |
dc.identifier.scopus | 2-s2.0-84971619944 | tr_TR |
dc.identifier.startpage | 945 | tr_TR |
dc.identifier.uri | https://doi.org/10.1007/s00296-016-3500-9 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00296-016-3500-9 | |
dc.identifier.uri | http://hdl.handle.net/11452/32973 | |
dc.identifier.volume | 36 | tr_TR |
dc.identifier.wos | 000378883700007 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Rheumatology International | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Rheumatology | en_US |
dc.subject | Secondary amyloidosis | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.subject | Ankylosing spondylitis | en_US |
dc.subject | Biologic therapy | en_US |
dc.subject | Anti-TNF | en_US |
dc.subject | AA amyloidosis | en_US |
dc.subject | Etanercept | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Criteria | en_US |
dc.subject | Tocilizumab | en_US |
dc.subject | Prevalence | en_US |
dc.subject | Infliximab | en_US |
dc.subject | Resolution | en_US |
dc.subject | Therapy | en_US |
dc.subject | Safety | en_US |
dc.subject.emtree | Abatacept | en_US |
dc.subject.emtree | Adalimumab | en_US |
dc.subject.emtree | Antirheumatic agent | en_US |
dc.subject.emtree | Creatinine | en_US |
dc.subject.emtree | Etanercept | en_US |
dc.subject.emtree | Infliximab | en_US |
dc.subject.emtree | Recombinant interleukin 1 receptor blocking agent | en_US |
dc.subject.emtree | Rituximab | en_US |
dc.subject.emtree | Salazosulfapyridine | en_US |
dc.subject.emtree | Tocilizumab | en_US |
dc.subject.emtree | Tumor necrosis factor inhibitor | en_US |
dc.subject.emtree | Biological product | en_US |
dc.subject.emtree | Immunosuppressive agent | en_US |
dc.subject.emtree | Tumor necrosis factor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Amyloidosis | en_US |
dc.subject.emtree | Ankylosing spondylitis | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Biological therapy | en_US |
dc.subject.emtree | Creatinine blood level | en_US |
dc.subject.emtree | Disease activity | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Evaluation study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Incidence | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Prevalence | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Proteinuria | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Rheumatoid arthritis | en_US |
dc.subject.emtree | Turkish citizen | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Amyloidosis | en_US |
dc.subject.emtree | Antagonists and inhibitors | en_US |
dc.subject.emtree | Arthritis, rheumatoid | en_US |
dc.subject.emtree | Chemically induced | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Disease course | en_US |
dc.subject.emtree | Immunocompromised patient | en_US |
dc.subject.emtree | Immunology | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Multicenter study | en_US |
dc.subject.emtree | Opportunistic İnfections | en_US |
dc.subject.emtree | Remission | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Spondylitis, ankylosing | en_US |
dc.subject.emtree | Time factor | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Tuberculosis | en_US |
dc.subject.emtree | Turkey | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Amyloidosis | en_US |
dc.subject.mesh | Arthritis, rheumatoid | en_US |
dc.subject.mesh | Biological products | en_US |
dc.subject.mesh | Disease progression | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunocompromised host | en_US |
dc.subject.mesh | Immunosuppressive agents | en_US |
dc.subject.mesh | Incidence | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Opportunistic infections | en_US |
dc.subject.mesh | Prevalence | en_US |
dc.subject.mesh | Remission induction | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Spondylitis, ankylosing | en_US |
dc.subject.mesh | Time factors | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.mesh | Tuberculosis | en_US |
dc.subject.mesh | Tumor necrosis factor-alpha | en_US |
dc.subject.mesh | Turkey | en_US |
dc.subject.scopus | Amyloidosis; Familial Mediterranean Fever; Congo Red | en_US |
dc.subject.wos | Rheumatology | en_US |
dc.title | A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: